Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)
Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%
Castle Biosciences EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Castle Biosciences's EV/EBITDA was 111.3× on Jan 30, 2026, against 42.0× a year earlier. Over the last 3 years it ranged from 6.0× to 113.4×, with a median of 46.5×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jan 30, 2026 | 111.3× | +1.8 |
| 2025 | Dec 31, 2025 | 109.5× | +71.1 |
| 2024 | Dec 31, 2024 | 38.3× | −61.8 |
| 2020 | Oct 30, 2020 | 100.2× | +45.6 |
| 2019 | Dec 31, 2019 | 54.6× | – |
See a number that looks wrong?